XML 66 R52.htm IDEA: XBRL DOCUMENT
v3.24.3

Commitments and Contingencies - License Agreements (Details) |  |  |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 27, 2023 shares | Jul. 19, 2023 $ / shares shares | Sep. 07, 2021 USD ($) shares | Nov. 01, 2019 USD ($) shares | Mar. 31, 2023 | Jun. 30, 2024 USD ($) | Mar. 27, 2023 item
Commitments and Contingencies |  |  |  |  |  |  |
Interest expense |  |  |  |  |  | $ 49,808 |
TheraCour Pharma Inc |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Percentage of net sales allocated for royalty payments (in percent) |  |  |  |  |  | 15.00% |
Related party | KMPL |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Percentage of clinical trials fees |  |  |  |  | 30.00% |  |
Percentage of royalty fee |  |  |  |  | 70.00% |  |
Number of clinical test drug candidates granted for the use, sale, or offer of sale in India | item |  |  |  |  |  |  | 2
Related party | TheraCour Pharma Inc |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Cash upon completion of Phase I Clinical Trials |  |  |  | $ 1,500,000 |  |  |
Cash upon completion of Phase II Clinical Trials |  |  |  | 2,500,000 |  |  |
Cash upon completion of Phase III Clinical Trials |  |  |  | $ 5,000,000 |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  | 75,000 |  |  |
Number of shares upon principle of note convertible | shares | 331,859 |  |  |  |  |  |
Gain on extinguishment |  |  |  |  |  | $ 49,808 |
Percentage of net sales allocated for royalty payments (in percent) |  |  |  | 15.00% |  |  |
Related party | TheraCour Pharma Inc | Unsecured promissory note |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Interest rate per annum (as a percent) |  | 12.00% |  |  |  |  |
Series A Preferred Stock | TheraCour Pharma Inc |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Number of shares upon principle of note convertible | shares |  | 331,859 |  |  |  |  |
Debt instrument, conversion stock, par value | $ / shares |  | $ 0.00001 |  |  |  |  |
Series A Preferred Stock | Related party |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Shares value upon initiation of Phase III Clinical Trials |  |  | $ 100,000 |  |  |  |
Series A Preferred Stock | Related party | TheraCour Pharma Inc |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |
Cash upon completion of Phase I Clinical Trials |  |  | 2,000,000 |  |  |  |
Cash upon completion of Phase II Clinical Trials |  |  | 2,500,000 |  |  |  |
Cash upon completion of Phase III Clinical Trials |  |  | $ 5,000,000 |  |  |  |
Number of shares issuable upon execution of agreement | shares |  |  | 100,000 |  |  |  |
Threshold Period for Issuance of Shares Upon Execution of Agreement |  |  | 30 days |  |  |  |
Stock Issued During Period Value New Issues Initiation Of Phase1 Clinical Trials |  |  | $ 1,500,000 |  |  |  |
Shares value upon completion of Phase III Clinical Trials |  |  | $ 500,000 |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  | 50,000 |  |  |  |
Percentage of net sales allocated for royalty payments (in percent) |  |  | 15.00% |  |  |  |

X
- Definition The line item information about commitment and contingencies. + References No definition available. + Details
Name: | nnvc_CommitmentsAndContingenciesLineItems
Namespace Prefix: | nnvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of clinical test drug candidates granted for the use, sale, or offer of sale in India. + References No definition available. + Details
Name: | nnvc_NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia
Namespace Prefix: | nnvc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of shares issuable upon execution of agreement. + References No definition available. + Details
Name: | nnvc_NumberOfSharesIssuableUponExecutionOfAgreement
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of clinical trials manager fee. + References No definition available. + Details
Name: | nnvc_PercentageOfClinicalTrialsFees
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty expense calculated as a percentage of net sales. + References No definition available. + Details
Name: | nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty fee paid. + References No definition available. + Details
Name: | nnvc_PercentageOfRoyaltyFee
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued during period shares new issues principle of note convertible. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon completion of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCompletionOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon initiation of phase I clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase1ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon initiation of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The threshold period for issuance of shares upon execution of agreement. + References No definition available. + Details
Name: | nnvc_ThresholdPeriodForIssuanceOfSharesUponExecutionOfAgreement
Namespace Prefix: | nnvc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentConvertibleStockPriceTrigger
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details
Name: | us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details
Name: | us-gaap_InterestExpenseDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_KarveerMeditechPvt.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=nnvc_UnsecuredPromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |